Sumitomo Pharma Raises Fiscal 2025 Forecast on Strong Drug Sales

MT Newswires Live

Apr 30, 2025

Sumitomo Pharma (TYO:4506) raised its forecast for fiscal 2025, including an attributable profit of 23.6 billion yen or 59.49 yen per share, driven by stronger-than-expected sales of prostate cancer drug and other products in North America, according to its filing on Tuesday.

This compares with the 16 billion yen or 40.27 yen per share previously forecasted.

Revenue is now expected at 398.8 billion yen from 381 billion yen initially.

A key boost came from the 11.9 billion yen gain recorded after transferring its regenerative medicine business to Racthera and Sumitomo Chemical in February.

This strategic move, alongside robust pharmaceutical performance, marks a turnaround from fiscal 2024's 314.9 billion yen net loss.

Shares of the company surged nearly 15% in morning trade Wednesday.

Price (JPY): $787.00, Change: $+100, Percent Change: +14.56%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2531341741"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531341741\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2531341741?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-30 09:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531341741","market":"nz","top_or_hot":-1,"title":"Sumitomo Pharma Raises Fiscal 2025 Forecast on Strong Drug Sales","media":"MT Newswires Live","content":"<html><body><p> Sumitomo Pharma (TYO:4506) raised its forecast for fiscal 2025, including an attributable profit of 23.6 billion yen or 59.49 yen per share, driven by stronger-than-expected sales of prostate cancer drug and other products in North America, according to its filing on Tuesday.</p><p>This compares with the 16 billion yen or 40.27 yen per share previously forecasted.</p><p>Revenue is now expected at 398.8 billion yen from 381 billion yen initially.</p><p>A key boost came from the 11.9 billion yen gain recorded after transferring its regenerative medicine business to Racthera and Sumitomo Chemical in February.</p><p>This strategic move, alongside robust pharmaceutical performance, marks a turnaround from fiscal 2024's 314.9 billion yen net loss.</p><p>Shares of the company surged nearly 15% in morning trade Wednesday.</p><p>Price (JPY): $787.00, Change: $+100, Percent Change: +14.56%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sumitomo Pharma Raises Fiscal 2025 Forecast on Strong Drug Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSumitomo Pharma Raises Fiscal 2025 Forecast on Strong Drug Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-30 09:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Sumitomo Pharma (TYO:4506) raised its forecast for fiscal 2025, including an attributable profit of 23.6 billion yen or 59.49 yen per share, driven by stronger-than-expected sales of prostate cancer drug and other products in North America, according to its filing on Tuesday.</p><p>This compares with the 16 billion yen or 40.27 yen per share previously forecasted.</p><p>Revenue is now expected at 398.8 billion yen from 381 billion yen initially.</p><p>A key boost came from the 11.9 billion yen gain recorded after transferring its regenerative medicine business to Racthera and Sumitomo Chemical in February.</p><p>This strategic move, alongside robust pharmaceutical performance, marks a turnaround from fiscal 2024's 314.9 billion yen net loss.</p><p>Shares of the company surged nearly 15% in morning trade Wednesday.</p><p>Price (JPY): $787.00, Change: $+100, Percent Change: +14.56%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JPY","symbol_name":"Lazard Japanese Equity ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2531341741","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531341741","pubTimestamp":1745975923,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sumitomo Pharma  raised its forecast for fiscal 2025, including an attributable profit of 23.6 billion yen or 59.49 yen per share, driven by stronger-than-expected sales of prostate cancer drug and other products in North America, according to its filing on Tuesday.This compares with the 16 billion yen or 40.27 yen per share previously forecasted.Revenue is now expected at 398.8 billion yen from 381 billion yen initially.A key boost came from the 11.9 billion yen gain recorded after transferring its regenerative medicine business to Racthera and Sumitomo Chemical in February.This strategic move, alongside robust pharmaceutical performance, marks a turnaround from fiscal 2024's 314.9 billion yen net loss.Shares of the company surged nearly 15% in morning trade Wednesday.Price : $787.00, Change: $+100, Percent Change: +14.56%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JPY":"Lazard Japanese Equity ETF"},"translate_title":"住友制药因药品销售强劲上调2025财年预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JPY":1},"content_text":"Sumitomo Pharma (TYO:4506) raised its forecast for fiscal 2025, including an attributable profit of 23.6 billion yen or 59.49 yen per share, driven by stronger-than-expected sales of prostate cancer drug and other products in North America, according to its filing on Tuesday.This compares with the 16 billion yen or 40.27 yen per share previously forecasted.Revenue is now expected at 398.8 billion yen from 381 billion yen initially.A key boost came from the 11.9 billion yen gain recorded after transferring its regenerative medicine business to Racthera and Sumitomo Chemical in February.This strategic move, alongside robust pharmaceutical performance, marks a turnaround from fiscal 2024's 314.9 billion yen net loss.Shares of the company surged nearly 15% in morning trade Wednesday.Price (JPY): $787.00, Change: $+100, Percent Change: +14.56%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}